CONSUN PHARMA (01681) announced that on June 13, 2025, the Board of Directors resolved to implement a share repurchase plan, authorizing the buyback of shares on the open market at appropriate times with a total fund allocation not exceeding HK$200 million (the "Previous Share Repurchase Plan"). On January 29, 2026, the Board resolved to execute an additional share repurchase plan under the buyback authority, for repurchasing shares on the open market at suitable times, increasing the total fund allocation by up to an additional HK$100 million beyond the amount for the Previous Share Repurchase Plan (the "Share Repurchase Plan"). Consequently, the total funds intended to be utilized for this combined Share Repurchase Plan will not exceed HK$300 million. The duration of the Share Repurchase Plan is from the date of this announcement until the conclusion of the company's next annual general meeting or until the shareholders revoke or amend the buyback authority at a general meeting. The Board of Directors expressed strong confidence in the company's business development and future prospects, believing that the current share price does not fully reflect its intrinsic value and long-term growth potential. The Board believes that, depending on prevailing market conditions and funding arrangements, the Share Repurchase Plan aligns with the company's long-term development strategy. Implementing the Share Repurchase Plan will optimize the management of the company's capital structure, enhance net asset value per share and/or earnings per share, and serve the overall interests of the company and its shareholders.